Skip to content

Anti-Mullerian Hormone levels after laparoscopic treatment in women with anovulatory polycystic ovary syndrome

Anti-Mullerian Hormone levels after laparoscopic treatment in women with anovulatory polycystic ovary syndrome

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015020420374N2
Enrollment
60
Registered
2015-03-23
Start date
2009-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Sclerocystic ovary syndrome

Interventions

Intervention 1: Unilateral ovarian laparoscopic treatment in patients with polycystic ovary syndrome who resistant to drug treatment with a daily dose of 250 mg clomiphene citrate. Intervention 2: Th
Treatment - Surgery
Treatment - Drugs
Unilateral ovarian laparoscopic treatment in patients with polycystic ovary syndrome who resistant to drug treatment with a daily dose of 250 mg clomiphene citrate
The control group was clomiphene citrate administration with dose of 250 mg daily for 6 months in patients with polycystic ovary syndrome

Sponsors

Vise chanceller for research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with polycystic ovary syndrome; PCOS patients resistance to drug clomiphene citrate; patients with symptoms of amenorrhea. Exclusion criteria: Patients with symptoms of oligomenorrhea; patients who were outside the age range.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum anti-mullerian levels. Timepoint: Pre-treatment and 1 week, 1 and 3 month after treatment. Method of measurement: Serum anti-mullerian hormon levels on nanomoles per mml.

Secondary

MeasureTime frame
Ovarian response to treatment method. Timepoint: 1 and 3 month. Method of measurement: The first menstural cycle after treatment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Esmat Aghadavod Jolfaie

Kashan university of Medical sciences

Aghadavod_m@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026